Activated B-cell immunophenotype might be associated with poor prognosis of primary central nervous system lymphomas

Bhagavathi, Sharathkumar; Sharathkumar, Anjali; Hunter, Susan; Sung, L; Kanhere, R.; Venturina, Mariza; Wilson, Jon D.

doi:10.5414/npp27013

Cited by 34 publications

(38 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, it was revealed that, unlike systemic DLBCLs, the majority of PCNSLs originate from post-GC, with a low expression of the GC marker CD10, expression of the GC marker BCL-6 and high expression of the activated B cell-like marker MUM-1, which is consistent with the majority of previous studies (14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)28,29) (Table III). In addition, the co-expression of BCL-6 and MUM-1 and the absence of late post-GC marker CD138 expression indicated the activated immunophenotype and the early post-GC origin of PCNSL, which was in accordance with Camilleri-Broёt et al (24).…”

Section: Discussionsupporting

confidence: 80%

“…Patients in the GCB subgroup showed an improved prognosis compared with ABC (activated B cell-like; including activated GCB and activated non-GCB, according to Chang's classification) (9,10,12,13). In PCNSL, numerous studies have been performed to observe the prognostic significance of the variable biological markers widely used in systemic DLBCL (14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24). The present study aimed to analyze the expression profile of immunohistochemical Immunohistochemical profile and prognostic significance in primary central nervous system lymphoma: Analysis of 89 cases markers and their potential prognostic significance in 89 Chinese PCNSL cases.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunohistochemical profile and prognostic significance in primary central nervous system lymphoma: Analysis of 89 cases

et al. 2017

View full text Add to dashboard Cite

Abstract. The majority of primary central nervous system lymphomas (PCNSLs) are diffuse large B cell lymphoma, characterized by poor prognosis. In the present study, the expression of cluster of differentiation (CD)10, B cell lymphoma (BCL)-6, multiple myeloma-1 (MUM-1), BCL-2, CD138 and Ki-67 was analyzed by immunohistochemistry in 89 Chinese PCNSL cases, and the potential prognostic significance was evaluated. CD10, BCL-6, MUM-1, BCL-2 and CD138 were positive in 16.9 (15/89), 51.7 (46/89), 92.1 (82/89), 73.3 (63/86) and 0% (0/65) of all cases, respectively. According to the Hans algorithm, 71 patients (79.8%) were classified into the non-germinal center B cell-like (non-GCB) group, indicating a post-germinal center origin of PCNSL. The median follow-up time of 73 patients was 13 months [95% confidence interval (CI), 10.93-15.08]. The median overall survival (OS) time was 45.3 months (95% CI, 25.01-65.59) and the median progression-free survival (PFS) time was 30.0 months (95% CI, 13.43-46.57). Age (>60 years) was associated with a shorter OS time (P=0.009). Ki-67 (cutoff point 90%) was associated with shorter OS (P=0.037) and shorter PFS (P=0.039) times. No other immunohistochemical markers were associated with prognosis. On multivariate analysis, age (>60 years) was associated with shorter OS time (P=0.038), but immunophenotype and expression status of Ki-67, CD10, BCL-6 and BCL-2 did not predict prognosis. In conclusion, high Ki-67 expression may predict poor prognosis in PCNSL. The present study was limited by its sample size and short follow-up time. This requires more evidence to further clinical study.

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Introductionmentioning

confidence: 99%

Immunohistochemical profile and prognostic significance in primary central nervous system lymphoma: Analysis of 89 cases

et al. 2017

View full text Add to dashboard Cite

show abstract

“…PCNSL has been reported to show an activated B-cell-like or germinal center B-cell-like subtype of DLBCL [3][4][5] ; however, recent studies of genome-wide gene expression in PCNSL compared with non-CNS DLBCL suggest that PCNSL has specific signatures to be distinguished from non-CNS DLBCL and greater molecular heterogeneity. 6,7 Tumor cells of PCNSL carry a heavy load of ongoing somatic hypermutation with biased use of VH genes in immunoglobulin gene analysis, suggesting an antigen-dependent proliferation.…”

Section: Introductionmentioning

confidence: 99%

Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma

Sung

Kim

Karnan

et al. 2011

Blood

View full text Add to dashboard Cite

Of the genetic changes in primary central nervous system lymphoma (PCNSL), little is known. To detect copy number alterations and differentially expressed genes in PCNSL, we analyzed a total of 12 PC-NSL samples with high-resolution arraybased comparative genomic hybridization and performed expression profiling in 7 of the 12 samples. The most frequent deletion found in 8 patients (66.7%) occurred in 9p21.3 containing CDKN2A. We compiled the top 96 genes (family-wise error rate, P < .05) showing the greatest differential expression between PCNSL and normal lymph node tissues. From these, we selected 8 candidate genes (NPFFR2, C4orf7, OSMR, EMCN, TPO, FNDC1, COL12A1, and MSC) in which expression changes were associated with copy number aberrations. All 8 genes showed both down-regulation in expression microarray and deletion in arraybased comparative genomic hybridization analyses. These genes participate in cell signaling or cell adhesion. In addition, low mRNA expression of C4orf7 was significantly associated with poor survival (P ‫؍‬ .0425). Using gene set enrichment analysis, we identified several signal transduction pathways, such as Janus kinase-signal transducers and activators of transcription pathway and adhesionrelated pathways, which may be involved in pathogenesis of PCNSL. In conclusion, this study identified novel tumor suppressor genes that may serve as therapeutic targets of PCNSL. (Blood. 2011;117(4): 1291-1300)

show abstract

“…The previous published data showed that the 2-year survival rates ranged from 34.8% to 65% and that a younger age was a better prognostic factor. 8,[21][22][23][24][25][26][27][28] Our data showed the 1-, 3-, and 5-year OS rates were 69%, 53%, and 43% respectively. For patients aged 670 years, the 1-, 3-, and 5-year survival rates were 87%, 74.2%, and 62.6% respectively.…”

Section: Discussionmentioning

confidence: 85%

“…[3][4][5][6] Two studies have shown that in the CNS, GCB DLBCL might have a better prognosis than ABC DLBCL. 7,8 However, several other studies did not reveal significant survival difference between these two groups. [9][10][11][12] These studies had either a limited total number of patients or very few patients in the GCB group.…”

Section: Introductionmentioning

confidence: 94%

Central nervous system lymphoma in immunocompetent patients: The North Shore-Long Island Jewish Health System experience

Zhang

Chen

Farmer

et al. 2013

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

Activated B-cell immunophenotype might be associated with poor prognosis of primary central nervous system lymphomas

Cited by 34 publications

References 0 publications

Immunohistochemical profile and prognostic significance in primary central nervous system lymphoma: Analysis of 89 cases

Immunohistochemical profile and prognostic significance in primary central nervous system lymphoma: Analysis of 89 cases

Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma

Central nervous system lymphoma in immunocompetent patients: The North Shore-Long Island Jewish Health System experience

Contact Info

Product

Resources

About